“Moderna has long touted that the mRNA vaccine technology it helped revolutionize during the global dash to create a coronavirus vaccine could be repurposed for a variety of medical uses. This vaccine, mRNA-4157, uses the method to train the immune system to identify and attack specific mutations in cancer cells.

The early-stage trial, conducted on patients already prescribed Merck’s Keytruda to treat certain types of head and neck cancer, produced some positive results — and hinted at an even brighter future for the vaccine.”

From The Daily Upside.